Christopher Goetz to Dyskinesia, Drug-Induced
This is a "connection" page, showing publications Christopher Goetz has written about Dyskinesia, Drug-Induced.
Connection Strength
3.090
-
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
Score: 0.567
-
Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
Score: 0.419
-
Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
Score: 0.380
-
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
Score: 0.350
-
The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
Score: 0.314
-
Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
Score: 0.306
-
Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
Score: 0.285
-
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
Score: 0.209
-
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
Score: 0.131
-
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
Score: 0.056
-
Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol. 2003; 91:213-28.
Score: 0.052
-
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
Score: 0.020